Clinical Biology and Potential Use of Thrombopoietin
The discovery of platelet growth factors raised expectations that an effective method for abrogating thrombocytopenia would soon be available in the clinic. The cytokines initially described were pleiotropic in nature, and stimulation of platelet production was generally modest. However, one of thes...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2000-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2000/681394 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559000920522752 |
|---|---|
| author | Russell Basser |
| author_facet | Russell Basser |
| author_sort | Russell Basser |
| collection | DOAJ |
| description | The discovery
of platelet growth factors raised expectations that an effective
method for abrogating thrombocytopenia would soon be available
in the clinic. The cytokines initially described were pleiotropic in
nature, and stimulation of platelet production was generally modest.
However, one of these agents, interleukin-11, was successfully
shown to reduce the incidence of severe thrombocytopenia in patients
receiving dose-intensive chemotherapy, and has now received
approval from the United States Food and Drug Administration
for this purpose. Initial clinical trials of thrombopoietin,
the central regulator of megakaryocytopoiesis and thrombopoiesis,
and its analogues showed these agents to be the most potent
stimulators of thrombopoiesis and to be associated with few adverse
effects. They have also been shown to enhance platelet recovery
after chemotherapy, but early results from trials investigating
their ability to prevent severe thrombocytopenia associated
with the treatment of leukemia and bone marrow transplantation
have been disappointing. In addition, subcutaneous administration
of one of these agents, megakaryocyte growth and development
factor, has been shown to induce the formation of antibodies
that neutralize native thrombopoietin and cause thrombocytopenia.
Platelet growth factors remain promising therapeutic
agents; however, there are a number of obstacles to overcome before
they find general use in the clinic. |
| format | Article |
| id | doaj-art-5fd4cb1a0d9748018fd3a506d11bbfd5 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2000-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-5fd4cb1a0d9748018fd3a506d11bbfd52025-02-03T01:31:02ZengWileyCanadian Journal of Gastroenterology0835-79002000-01-0114Suppl D73D78D10.1155/2000/681394Clinical Biology and Potential Use of ThrombopoietinRussell Basser0Departments of Haematology and Medical Oncology, Royal Melbourne Hospital and Western Hospital, Victoria, AustraliaThe discovery of platelet growth factors raised expectations that an effective method for abrogating thrombocytopenia would soon be available in the clinic. The cytokines initially described were pleiotropic in nature, and stimulation of platelet production was generally modest. However, one of these agents, interleukin-11, was successfully shown to reduce the incidence of severe thrombocytopenia in patients receiving dose-intensive chemotherapy, and has now received approval from the United States Food and Drug Administration for this purpose. Initial clinical trials of thrombopoietin, the central regulator of megakaryocytopoiesis and thrombopoiesis, and its analogues showed these agents to be the most potent stimulators of thrombopoiesis and to be associated with few adverse effects. They have also been shown to enhance platelet recovery after chemotherapy, but early results from trials investigating their ability to prevent severe thrombocytopenia associated with the treatment of leukemia and bone marrow transplantation have been disappointing. In addition, subcutaneous administration of one of these agents, megakaryocyte growth and development factor, has been shown to induce the formation of antibodies that neutralize native thrombopoietin and cause thrombocytopenia. Platelet growth factors remain promising therapeutic agents; however, there are a number of obstacles to overcome before they find general use in the clinic.http://dx.doi.org/10.1155/2000/681394 |
| spellingShingle | Russell Basser Clinical Biology and Potential Use of Thrombopoietin Canadian Journal of Gastroenterology |
| title | Clinical Biology and Potential Use of Thrombopoietin |
| title_full | Clinical Biology and Potential Use of Thrombopoietin |
| title_fullStr | Clinical Biology and Potential Use of Thrombopoietin |
| title_full_unstemmed | Clinical Biology and Potential Use of Thrombopoietin |
| title_short | Clinical Biology and Potential Use of Thrombopoietin |
| title_sort | clinical biology and potential use of thrombopoietin |
| url | http://dx.doi.org/10.1155/2000/681394 |
| work_keys_str_mv | AT russellbasser clinicalbiologyandpotentialuseofthrombopoietin |